Company: RGBP
Filing Date: 2025-02-24
Form Type: 253G1
Source: 0001493152-25-008067
Chunk: 5

Company: Regen BioPharma Inc
Filing Date: 2025-02-24
Form: 253G1
Chunk 5
---
 to original shareholders      |     | $           |  0.00 |   |     | $           |  0.01 |   |     | $           |  0.02 |   |     | $           |  0.04 |   |     | $           |  0.04 |   |
| Decrease in investment to new shareholders |     | $           |  0.20 |   |     | $           |  0.19 |   |     | $           |  0.18 |   |     | $           |  0.16 |   |     | $           |  0.16 |   |
| Dilution percentage to new shareholders    |     |             |   500 | % |     |             |   475 | % |     |             |   450 | % |     |             |   400 | % |     |             |   400 | % |

* Based on book value as of 9/30/2024, based upon $0.04 offering price, includes 15,426,385 common distributed as a dividend to all shareholders of record as of October 17, 2024 (“Record Date”) paid to shareholders on or about November 1, 2024

RISK FACTORS

An investment in our common stock involves a high degree of risk. You should carefully consider the risks described below as well as other information provided to you in this Offering Circular, including information in the section of this document entitled “CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS”. If any of the following risks actually occur, our business, financial condition or results of operations could be materially adversely affected, the value of our common stock could decline, and you may lose all or part of your investment. The following discussion and analysis should be read in conjunction with the other financial information and consolidated financial statements and related notes appearing in this Offering Circular.

| 7 |

Risks Related to our Business:

THERE IS SUBSTANTIAL DOUBT ABOUT THE COMPANY’S ABILITY TO CONTINUE AS A GOING CONCERN.

The Company generated net losses of $20,616,114 during the period from April 24, 2012 (inception) through September 30, 2024. This condition raises substantial doubt about the Company’s ability to continue as a going concern. The Company’s continuation as a going concern is dependent on its ability to meet